Akinchan Bhardwaj: Targeting SBK2 for Selective Inflammasome Resolution in Atherosclerosis
Akinchan Bhardwaj, Consultant Interventional Cardiologist at Kauvery Hospital, shared a post on LinkedIn about a recent article by Liangyu Cai et al, published in European Heart Journal:
“A new therapeutic target in atherosclerosis?
What if the key to treating atherosclerosis is not blocking inflammation, but resolving it?
A new study in the European Heart Journal explores something fascinating:
In advanced plaques, macrophages upregulate a kinase called SBK2.
At first glance, that looks like part of the problem. But it turns out to be part of the solution.
When SBK2 was genetically deleted, plaques worsened.
When SBK2 was overexpressed in macrophages, inflammation and plaque burden decreased.
Why?
Because SBK2 phosphorylates NLRP3, enabling its selective autophagic degradation.
In simpler terms:
The cell is not just trying to shut down inflammation.
It is trying to clear the inflammasome machinery itself.
Instead of broadly suppressing IL-1β or IL-18, this pathway promotes targeted resolution at the level of inflammasome regulation.
Even more interesting:
A small molecule (rebaudioside N) activated SBK2 and reduced plaque burden and the effect disappeared in SBK2-deficient models.
That level of target specificity is rare in preclinical inflammation research.
It reinforces a broader shift in cardiovascular biology:
Atherosclerosis is not merely lipid accumulation.
It is an immunologic microenvironment with compensatory protective circuits we barely understand.
The question for translation becomes:
Can we enhance endogenous protective pathways without impairing host defense?
If kinase-driven inflammasome resolution proves viable in humans, it may represent a new paradigm in inflammatory cardiovascular risk reduction.
The future of prevention may lie not only in lowering LDL but in precisely modulating immune balance inside the plaque. That is exciting.
Would selective inflammasome resolution be safer than systemic cytokine blockade in ASCVD?”
Title: Macrophage SBK2 suppresses inflammation and atherosclerosis by NLRP3 phosphorylation
Authors: Liangyu Cai, Changhao Liu, Haonan Zheng, Qian Li, Liwen Yu, Xiaohong Wang, Yujie Zhang, Wei Yang, Ruiqing Ren, Guohai Su, Bo Li, Lei Cao, Jie Zhang, Yun Zhang, Cheng Zhang, Meng Zhang
Read the Full Article on European Heart Journal
Stay updated with Hemostasis Today.
-
Oct 21, 2026, 08:29Andreas Kronbichler: The Changing Landscape of CV Risk in ANCA-Associated Vasculitis
-
Oct 21, 2026, 08:21Pham Quy: Taking Stroke Awareness Beyond Hospitals and Into the Community
-
Oct 21, 2026, 07:15Mahmoud Saad: Successful Mechanical Thrombectomy for Right Atrial Thrombosis
-
Oct 21, 2026, 06:55Hunain Shahbaz: Extended Dual Antiplatelet Therapy Beyond 12 Months After Drug-Eluting Stent Implantation
-
Oct 21, 2026, 06:19Dawood Findakly: When Should Anticoagulation Be Held or Resumed?
-
Oct 21, 2026, 03:36Steve Watson: Ligand Epitope Ratios Influence Antagonist Inhibition
-
Oct 21, 2026, 03:18Stephen D. Coombs: Superficial Venous Thrombosis in Athletes and Importance of Early Recognition and Referral
-
Oct 21, 2026, 02:52Aymar Akilimali: Bleeding During Anticoagulation as a Potential Signal of Occult Cancer
-
Oct 21, 2026, 00:58Anees Ur Rahman: Completing a Two-Week Clinical Rotation at Haemophilia Treatment Centre Rawalpindi